Capricor Therapeutics, Inc. (CAPR) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1151853,
    "name": "Capricor Therapeutics, Inc.",
    "stock_name": "Capricor Therapeutics, Inc.",
    "full_name": "Capricor Therapeutics, Inc.",
    "name_url": "stocks-analysis/capricor-therapeutics-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "25.40",
    "chg": 19.04,
    "chgp": "299.37%",
    "dir": 1,
    "prev_price": "6.36",
    "mcapval": "290.30",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US14070B3096",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "2.98 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/capricor-therapeutics-inc-1151853-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Capricor Therapeutics Hits New 52-Week Low at $4.40 Amid Financial Struggles",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/capricor-therapeutics-hits-new-52-week-low-at-440-amid-financial-struggles-3729421",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/CapricorTherape_priceRelatedfactors_3729421.png",
        "date": "2025-11-25 16:23:00",
        "description": "Capricor Therapeutics, Inc. has reached a new 52-week low, reflecting a significant decline in its stock performance. The company reported a 46.91% drop in net sales for the first nine months, alongside a negative operating cash flow and rising raw material costs, indicating ongoing financial challenges."
      },
      {
        "title": "Capricor Therapeutics Hits 52-Week Low at $5.43 Amid Financial Struggles",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/capricor-therapeutics-hits-52-week-low-at-543-amid-financial-struggles-3690319",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/CapricorTherape_priceRelatedfactors_3690319.png",
        "date": "2025-11-11 18:07:12",
        "description": "Capricor Therapeutics, Inc. has hit a new 52-week low, reflecting a significant decline in its stock value over the past year. The company reported a 46.91% drop in net sales and a negative operating cash flow, compounded by rising raw material costs. Its financial metrics indicate ongoing challenges."
      },
      {
        "title": "Is Capricor Therapeutics, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-capricor-therapeutics-inc-technically-bullish-or-bearish-3546891",
        "imagepath": "",
        "date": "2025-09-20 19:42:32",
        "description": "As of 17 July 2025, the technical trend for Capricor Therapeutics, Inc. has changed from mildly bearish to bearish. The current stance is bearish with a weak strength indicated by the weekly MACD and KST both showing bearish signals, and daily moving averages confirming a bearish trend. The Bollinger Bands are also mildly bearish on both weekly and monthly time frames. Despite a 1-year return of 25.00%, which outperforms the S&P 500's 17.14%, the year-to-date return of -53.62% significantly lags behind the S&P 500's 12.22%. Overall, the technical indicators suggest a bearish outlook for the stock...."
      },
      {
        "title": "Is Capricor Therapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-capricor-therapeutics-inc-overvalued-or-undervalued-3543373",
        "imagepath": "",
        "date": "2025-09-20 18:17:39",
        "description": "As of 10 November 2022, the valuation grade for Capricor Therapeutics, Inc. moved from does not qualify to risky, indicating a shift towards greater concern regarding its financial health. The company appears to be overvalued, as evidenced by its high Price to Book Value of 5.10 and negative EV to EBIT and EV to EBITDA ratios of -8.90 and -9.14, respectively. Additionally, the Return on Equity (ROE) stands at a concerning -43.14%, further highlighting the company's struggles.\n\nIn comparison to its peers, Capricor's valuation metrics are less favorable; for instance, Chimerix, Inc. has a more negative EV to EBITDA of -6.6011, while CytomX Therapeutics, Inc. is classified as very attractive with a P/E of 7.4924. The stock has underperformed against the S&P 500 in several periods, notably with a year-to-date return of -53.62% compared to the S&P 500's 12.22%, reinforcing the notion that Capricor may be overval..."
      }
    ],
    "total": 9,
    "sid": "1151853",
    "stock_news_url": "https://www.marketsmojo.com/news/capricor-therapeutics-inc-1151853"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Capricor Therapeutics Hits New 52-Week Low at $4.40 Amid Financial Struggles

2025-11-25 16:23:00

Capricor Therapeutics, Inc. has reached a new 52-week low, reflecting a significant decline in its stock performance. The company reported a 46.91% drop in net sales for the first nine months, alongside a negative operating cash flow and rising raw material costs, indicating ongoing financial challenges.

Capricor Therapeutics Hits 52-Week Low at $5.43 Amid Financial Struggles

2025-11-11 18:07:12

Capricor Therapeutics, Inc. has hit a new 52-week low, reflecting a significant decline in its stock value over the past year. The company reported a 46.91% drop in net sales and a negative operating cash flow, compounded by rising raw material costs. Its financial metrics indicate ongoing challenges.

Is Capricor Therapeutics, Inc. technically bullish or bearish?

2025-09-20 19:42:32

As of 17 July 2025, the technical trend for Capricor Therapeutics, Inc. has changed from mildly bearish to bearish. The current stance is bearish with a weak strength indicated by the weekly MACD and KST both showing bearish signals, and daily moving averages confirming a bearish trend. The Bollinger Bands are also mildly bearish on both weekly and monthly time frames. Despite a 1-year return of 25.00%, which outperforms the S&P 500's 17.14%, the year-to-date return of -53.62% significantly lags behind the S&P 500's 12.22%. Overall, the technical indicators suggest a bearish outlook for the stock....

Is Capricor Therapeutics, Inc. overvalued or undervalued?

2025-09-20 18:17:39

As of 10 November 2022, the valuation grade for Capricor Therapeutics, Inc. moved from does not qualify to risky, indicating a shift towards greater concern regarding its financial health. The company appears to be overvalued, as evidenced by its high Price to Book Value of 5.10 and negative EV to EBIT and EV to EBITDA ratios of -8.90 and -9.14, respectively. Additionally, the Return on Equity (ROE) stands at a concerning -43.14%, further highlighting the company's struggles. In comparison to its peers, Capricor's valuation metrics are less favorable; for instance, Chimerix, Inc. has a more negative EV to EBITDA of -6.6011, while CytomX Therapeutics, Inc. is classified as very attractive with a P/E of 7.4924. The stock has underperformed against the S&P 500 in several periods, notably with a year-to-date return of -53.62% compared to the S&P 500's 12.22%, reinforcing the notion that Capricor may be overval...

View All News